Is the ATH cryptocurrency worth buying? Analysts expect the cryptocurrency to decline after the Nasdaq-linked DePIN's $344 million financial plan was announced on Aethir.

The Nasdaq-listed biotech company Predictive Oncology has committed to invest $344 million in Aethir's ATH token, becoming the first U.S. listed company to hold DePIN network tokens as assets on its balance sheet. This financing includes $51.7 million in cash PIPE and $292.7 million in cryptocurrency PIPE, with the proceeds intended for purchasing ATH on the open market and providing a 20% token reward. CEO Raymond Vennare emphasized the strategic partnership between both parties in AI-driven drug development. The price of ATH has shown bullish momentum after breaking through a key downtrend, consolidating around $0.064-$0.065, with support at $0.055-$0.057.